ProxsysRx Names Matthew A. King to Board of Directors

  • Home
  • ProxsysRx Names Matthew A. King to Board of Directors

ProxsysRx Names Matthew A. King to Board of Directors

BIRMINGHAM, AL The Board of Directors of ProxsysRx announces the election of healthcare executive and venture capitalist Matthew A. King of Nashville to the company’s Board of Directors. Mr. King serves as Managing Partner of Clayton and Associates FCA Ventures and Diōko Health Ventures. He is Managing Partner of Triple Play Ventures, an investment partnership that started in 1999.

Mr. King has more than 35 years of business experience, the last 18 of which have been exclusively in the venture capital industry with a focus on healthcare services and information technology. He has participated in approximately 55 venture capital and private equity investments since 1992 and has served as lead investor in 27 transactions for FCA Ventures. Mr. King currently serves on the boards of directors of Clinical Ink, Inc., StudioNow, Inc., MediQuire, Inc., Remedly, Inc., HealthyBytes, Inc. Vericred, Inc., and all FCA and Diōko portfolio companies.

Mr. King serves as Lead Director of Truxton Trust Company (OTC: TRUX),  a Director of Wake Forest University Health Sciences, and as a Trustee for Wake Forest University.
“We are thrilled to welcome Matt to the Board; he brings deep experience in finance and healthcare IT at a time when ProxsysRx is experiencing phenomenal growth,” said ProxsysRx Chairman and CEO George B. Salem, who notes that King steps into the ProxsysRx Board seat previously held by Stuart McWhorter, who now serves as Commissioner of the Department of Finance and Administration for the state of Tennessee.

ProxsysRx is a pharmacy-based healthcare solutions company that vertically integrates outpatient pharmacy into the continuum of care for health systems and affiliated contracting agents. ProxsysRx provides multiple product lines to drive value in distinct areas for health systems. Benefits include reduced readmission rates, decreased employee pharmacy benefit costs, increased 340 B savings, increased patient satisfaction, and a robust Meds to Beds program. Additional information is available at

Media Contact: Melanie McCraney
McCraney Communications for ProxsysRx